Clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis stage and grade: An exploratory sub-analysis of the ABPARO trial.

Peter EickholzRaphael KochMoritz GödeKatrin NicklesThomas KocherKatrin LorenzTi-Sun KimJoerg MeyleDoğan KanerUlrich SchlagenhaufInga HarksBenjamin Ehmke

Published in: Journal of clinical periodontology (2023)

In generalized periodontitis stage III/grade C, a clinically relevant lower percentage of disease progression after adjunctive systemic amoxicillin/metronidazole was observed compared to placebo (PLAC: 9.7; 5.8/14.3% vs. ANTI: 4.7; 2.4/9.0%; p < .001).

Keyphrases

phase iii
clinical trial
study protocol
phase ii
double blind
open label
placebo controlled